← Leaderboards
Ashlee V Moses
Oregon Health And Science University
$16,021,438
Attributed
$16,269,783
Total exposure
24
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2005–23$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$16,269,783 · 24
By mechanism
R01$9,909,154 · 6
U54$3,525,519 · 1
P51$2,362,784 · 15
T32$372,518 · 1
R41$99,808 · 1
Top collaborators
- Scott M Landfear1 shared
- Jeffrey C. Nolz1 shared
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsEndothelial CellsProteinsViralPlayPathway InteractionsIn VitroBaseMalignant NeoplasmsIn VivoLeadKaposi SarcomaTumorPathogenesisHuman Herpesvirus 8PhenotypeInfectionGrowthHiv-1Acquired Immunodeficiency SyndromeInhibitor/AntagonistHiv InfectionsGenesAffect
Grant awards (57)
Interdisciplinary Training in Microbial Pathogenesis and Immunology$372,518
T32 · FY2023 · AI
KSHV Manipulates Host Iron Metabolism and Ferroptotic Cell Death Pathways, Creating Novel Vulnerability Points for Therapeutic Intervention.$352,275
R01 · FY2023 · CA · contact PI
KSHV Manipulates Host Iron Metabolism and Ferroptotic Cell Death Pathways, Creating Novel Vulnerability Points for Therapeutic Intervention.$1
R01 · FY2022 · CA · contact PI
KSHV Manipulates Host Iron Metabolism and Ferroptotic Cell Death Pathways, Creating Novel Vulnerability Points for Therapeutic Intervention.$352,275
R01 · FY2021 · CA · contact PI
KSHV Manipulates Host Iron Metabolism and Ferroptotic Cell Death Pathways, Creating Novel Vulnerability Points for Therapeutic Intervention.$352,275
R01 · FY2020 · CA · contact PI
Heme oxygenase-1 as a tumor factor and therapeutic target for Kaposi sarcoma$337,105
R01 · FY2019 · CA · contact PI
Heme oxygenase-1 as a tumor factor and therapeutic target for Kaposi sarcoma$347,532
R01 · FY2018 · CA · contact PI
Heme oxygenase-1 as a tumor factor and therapeutic target for Kaposi sarcoma$393,725
R01 · FY2017 · CA · contact PI
Heme oxygenase-1 as a tumor factor and therapeutic target for Kaposi sarcoma$395,372
R01 · FY2016 · CA · contact PI
Heme oxygenase-1 as a tumor factor and therapeutic target for Kaposi sarcoma$400,313
R01 · FY2015 · CA · contact PI
Characterization of Vpu-mediated degradation of BST-2$405,900
R01 · FY2014 · AI · contact PI
Mechanisms of KSHV-Induced Cellular Transformation$251,949
R01 · FY2014 · CA · contact PI
Development Research Plan$613,793
U54 · FY2013 · AI · contact PI
Characterization of Vpu-mediated degradation of BST-2$381,546
R01 · FY2013 · AI · contact PI
Mechanisms of KSHV-Induced Cellular Transformation$257,281
R01 · FY2013 · CA · contact PI
Development Research Plan$1,068,870
U54 · FY2012 · AI · contact PI
Characterization of Vpu-mediated degradation of BST-2$405,900
R01 · FY2012 · AI · contact PI
Mechanisms of KSHV-Induced Cellular Transformation$259,741
R01 · FY2012 · CA · contact PI
Development Research Plan$623,864
U54 · FY2011 · AI · contact PI
Characterization of Vpu-mediated degradation of BST-2$405,900
R01 · FY2011 · AI · contact PI
Mechanisms of KSHV-Induced Cellular Transformation$249,814
R01 · FY2011 · CA · contact PI
Development Research Plan$605,717
U54 · FY2010 · AI · contact PI
Characterization of Vpu-mediated degradation of BST-2$410,000
R01 · FY2010 · AI · contact PI
Mechanisms of KSHV-Induced Cellular Transformation$260,074
R01 · FY2010 · CA · contact PI
MECHANISMS OF KSHV-INDUCED CELLULAR TRANSFORMATION$152,161
P51 · FY2010 · RR · contact PI
THE ROLE OF HIV-1 VPU IN THE REGULATION OF CD40$152,161
P51 · FY2010 · RR · contact PI
Development Research Plan$613,275
U54 · FY2009 · AI · contact PI
The Role of HIV-1 Vpu in the Regulation of CD40$316,025
R01 · FY2009 · AI · contact PI
MECHANISMS OF KSHV-INDUCED CELLULAR TRANSFORMATION$165,284
P51 · FY2009 · RR · contact PI
THE ROLE OF HIV-1 VPU IN THE REGULATION OF CD40$88,613
P51 · FY2009 · RR · contact PI
Role of HIV-1 Vpu in the Regulation of CD40$316,025
R01 · FY2008 · AI · contact PI
Mechanisms of KSHV-Induced Cellular Transformation$234,807
R01 · FY2008 · CA · contact PI
THE ROLE OF HIV-1 VPU IN THE REGULATION OF CD40$176,141
P51 · FY2008 · RR · contact PI
MECHANISMS OF KSHV-INDUCED CELLULAR TRANSFORMATION$176,141
P51 · FY2008 · RR · contact PI
Role of HIV-1 Vpu in the Regulation of CD40$322,145
R01 · FY2007 · AI · contact PI
Mechanisms of KSHV-Induced Cellular Transformation$234,807
R01 · FY2007 · CA · contact PI
THE ROLE OF HIV-1 VPU IN THE REGULATION OF CD40$225,890
P51 · FY2007 · RR · contact PI
MECHANISMS OF KSHV-INDUCED CELLULAR TRANSFORMATION$225,890
P51 · FY2007 · RR · contact PI
The Role of HIV-1 Vpu in the Regulation of CD40$331,767
R01 · FY2006 · AI · contact PI
Mechanisms of KSHV-Induced Cellular Transformation$241,820
R01 · FY2006 · CA · contact PI
MECHANISMS OF KSHV-INDUCED CELLULAR TRANSFORMATION$131,162
P51 · FY2006 · RR · contact PI
THE ROLE OF HIV-1 VPU IN THE REGULATION OF CD40$131,162
P51 · FY2006 · RR · contact PI
Role of HIV-1 Vpu in the Regulation of CD40$339,750
R01 · FY2005 · AI
Mechanisms of KSHV-Induced Cellular Transformation$247,640
R01 · FY2005 · CA
MECHANISMS OF KSHV-INDUCED CELLULAR TRANSFORMATION$94,156
P51 · FY2005 · RR
EVALUATION OF NOVEL ANTI-VIRAL TARGETS IN THE SIV MACAQUE SYSTEM$94,156
P51 · FY2005 · RR
Mechanisms of KSHV-Induced Cellular Transformation$247,640
R01 · FY2004 · CA
IDENTIFYING CELLULAR GENES AS ANTI-HIV DRUG TARGETS$105,323
P51 · FY2004 · RR
EVALUATION OF NOVEL ANTI-VIRAL TARGETS IN THE SIV MACAQUE SYSTEM$105,323
P51 · FY2004 · RR
HIV-INFECTED ENDOTHELIUM AND NON-HODGKIN'S LYMPHOMA$105,323
P51 · FY2004 · RR
MECHANISMS OF KSHV-INDUCED CELLULAR TRANSFORMATION$105,323
P51 · FY2004 · RR
Identifying cellular genes as anti-HIV drug targets$99,808
R41 · FY2003 · AI
HIV INFECTED ENDOTHELIUM AND NONHODGKINS LYMPHOMA$260,750
R01 · FY2002 · HL
HIV INFECTED ENDOTHELIUM AND NONHODGKINS LYMPHOMA$75,500
R01 · FY2002 · HL
HIV INFECTED ENDOTHELIUM AND NONHODGKINS LYMPHOMA$260,750
R01 · FY2001 · HL
HIV INFECTED ENDOTHELIUM AND NONHODGKINS LYMPHOMA$260,750
R01 · FY2000 · HL
EFFECT OF SIV ON HEMATOPOIESIS$128,575
P51 · FY2000 · RR